CDT Equity (CDT) Restructuring Costs (2024 - 2025)
CDT Equity's (CDT) quarterly Restructuring Costs came in at $1.0 million in Q3 2025, up 2.9% on a YoY basis from $999000.0 in Q3 2024, and down 5.77% quarter-over-quarter from $1.1 million in Q2 2025.
Powered by 
Analysis
CDT Equity (CDT) Restructuring Costs (2024 - 2025) Analysis & Trends
CDT Equity (CDT) has reported Restructuring Costs for 2 consecutive years, with $1.0 million the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Restructuring Costs rose 2.9% year-over-year to $1.0 million; the trailing twelve-month figure through Sep 2025 stood at $4.0 million (changed N/A YoY), and the FY2024 full-year result was $4.1 million, up 278.38% from the prior year.
- Restructuring Costs declined to $1.0 million in Q3 2025 per CDT's latest filing, from $1.1 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $1.1 million in Q4 2024 and bottomed at $703000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 640.79 Bn | 620.03 Bn | 17.26 Bn |
| 2 | AbbVie | 445.95 Bn | 439.38 Bn | 12.70 Bn |
| 3 | Merck | 357.40 Bn | 350.26 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.40 Bn | 259.71 Bn | 11.24 Bn |
| 5 | Pfizer | 156.52 Bn | 144.82 Bn | 10.94 Bn |
| 6 | Sanofi | 52.15 Bn | 44.77 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.02 Bn | 43.02 Bn | - |
| 8 | Incyte | 24.59 Bn | 20.06 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.31 Bn | 18.64 Bn | 683.80 Mn |
| 10 | CDT Equity | 179,140.97 | 179,140.97 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | 703,000.00 |
| Dec 31, 2024 | 1.15 Mn |
| Sep 30, 2024 | 999,000.00 |
| Jun 30, 2024 | 964,000.00 |
| Mar 31, 2024 | 949,000.00 |